Analyst Research Report Snapshot

Title:

MAGFORCE - COMING OUT IN FORCE

Price:

$10.00

Provider:

Edison Investment Research

Date:

27 Nov 2013

Pages:

12

Type:

AcrobatPDF

Companies referenced:

MF6G.DE NANOB.PA SRX.AX

Available for Immediate Download
Summary:

MagForce is well positioned to execute on its strategy to increase uptake of its novel NanoTherm therapy, which is already approved in Europe for brain cancer. A new glioblastoma study due to start imminently should help increase awareness and acceptance of this treatment. MagForce is also intending to enter the US market and to develop NanoTherm therapy for prostate cancer. Our risk-adjusted valuation is €197m or €8.2/share.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.